The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the potential benefits of 145 mg of daily
fenofibrate in adults with type 1 diabetes mellitus and pre-existing non-proliferative
diabetic retinopathy.
Phase:
Phase 3
Details
Lead Sponsor:
University of Sydney
Collaborators:
Abbott Juvenile Diabetes Research Foundation Australia Melbourne Health Mylan Pharmaceuticals National Health and Medical Research Council, Australia Royal Prince Alfred Hospital, Sydney, Australia St Vincent's Hospital Melbourne University of Melbourne